---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-22-000049"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2022-08-31T23:59:59+00:00"
generated_at: "2026-06-23T18:29:27.258607+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Imsidolimab HARP Phase 2 fails to beat placebo in hidradenitis suppurativa; HS development halted

## Summary
- Imsidolimab did not improve primary endpoint (AN count change) or HiSCR50 vs placebo at Week 16 in moderate-to-severe HS.
- No imsidolimab-related serious/severe AEs; safety profile acceptable across arms.
- Company discontinues imsidolimab development in HS; GEMINI-1 Phase 3 for GPP continues with data expected Q4 2023.
- Plans to outlicense imsidolimab prior to potential FDA approval for GPP; focus on rosnilimab and ANB032 immune cell modulators.
- Cash over $570M at Q2 end; AZURE Phase 2 rosnilimab data in alopecia areata anticipated Q1 2023.

## SEC filing metadata
- accession: 0001370053-22-000049
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2022-08-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005322000049/0001370053-22-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005322000049/anab-20220831.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-22-000049
- JSON: https://secwatch.observer/filing/0001370053-22-000049.json
- Plain text: https://secwatch.observer/filing/0001370053-22-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.